Phase 2/3RecruitingHealthspan endpoint
Focusing on the Menopausal Transition to Improve Mid-Life Women's Health
- Sponsor
- University of Colorado, Denver (Academic or other)
- Enrollment
- 200 planned
- Conditions
- Menopause; Menopause Hot Flashes; Menopause Related Conditions; Cardiovascular
- Interventions
- Metformin; semaglutide; Anti-hypertensives; Lipid Lowering Medication; Life style intervention; Fezolinetant; Hormonal therapy
- Ages
- adults
- Registry
- NCT06975111
Full record on ClinicalTrials.gov
From the registry
What if midlife women, who are inherently at an increased risk for future cardiometabolic disease due to transitioning into menopause, had access to a suite of evidence-based health interventions? Could these interventions reduce menopause-related inflammation, restore a healthier cardiometabolic profile, reverse epigenetic aging, and reduce bothersome menopausal symptoms? The ultimate goal of this work is to attenuate future disease and enhance women's quality of life, extend healthspan and increase productivity.
Primary outcomes
- Epigenetic aging measurements of "PhenoAge"
- Epigenetic aging measurements of "GrimAge"
History
Study completion expected
Primary completion expected
Last registry update
Started
Registered
In the news
ResearchDeutsches Ärzteblatt (opens Deutsches Ärzteblatt in a new tab)
Researchers find weight loss cannot fully explain semaglutide’s 20% cardiovascular risk reduction
The SELECT mediation analysis examined 24-month risk-factor changes in adults with cardiovascular disease, BMI ≥27 and no diabetes, assigned to weekly semaglutide targeting 2.4 mg or placebo.
